Inclacumab was generally well tolerated in THRIVE-131
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Phase 1 dosing is expected to finish by the end of 2025
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Subscribe To Our Newsletter & Stay Updated